When was MannKind Corp founded?

MannKind Corp was founded in 1991 and raised its 1st funding round 13 years after it was founded.

Where is MannKind Corp located?

MannKind Corp is headquartered in Los Angeles, United States. It is registered at 30930 Russell Ranch Road Suite 300 Westlake Village, CA 91362.

How many employees does MannKind Corp have?

As of May 31, 2026, the latest employee count at MannKind Corp is 833.

Is MannKind Corp a funded company?

MannKind Corp is a funded company, having raised a total of $50M across 8 funding rounds to date. The company's 1st funding round was a $***** Series B round, raised on Jan 2004.

When was the latest funding round of MannKind Corp?

MannKind Corp's latest funding was a $***** Post IPO round on Mar 01, 2021, with participation from 0 investor. Its primary sector is Drug Delivery. In United States, the Drug Delivery sector has seen $196M in funding in 2026 to date.

What is the annual revenue of MannKind Corp?

Annual revenue of MannKind Corp is between $100M and $500M as on Dec 31, 2025

Where does MannKind Corp rank among its competitors?

MannKind Corp ranks 2nd amongst 114 active competitors, of which 31 are funded. It stands 5th in terms of total funding among its competitors. The most recent competitor to raise funding was Sernova, which secured $345K in Oct, 2025.

Who are the top competitors of MannKind Corp?

MannKind Corp's top competitors include Rhythm Pharmaceuticals, Corcept and 89bio. Among them, Sernova secured the most recent funding round in October, 2025.

MannKind Corp - 2026 Company Profile, Funding, Competitors & Financials

Company Details

MannKind Corporation focuses on the discovery, development, and commercialization of a variety of therapeutic products through its proprietary drug delivery technology. The company's Technosphere formulation technology uses Technosphere Particles for pulmonary delivery of small molecules, peptides, and proteins directly by inhalation and thus helps in rapid drug absorption, bypassing the liver and also in enhancing bioavailability. The dry powder formulations are made with FDA approved excipients. The company also has proprietary products for inhalation profiling and single multi-use inhalers. The company's lead product includes Afrezza (inhalable ultra-rapid-acting insulin).

Website: mannkindcorp.com
Social
Registered Address: 30930 Russell Ranch Road Suite 300 Westlake Village, CA 91362

Key Metrics

Founded Year

1991

Location

Los Angeles, United States

Stage

Public

Total Funding

$50M in 8 rounds

Latest Funding Round

Post IPO, Mar 01, 2021, $*****

Investors

Colt Ventures & 2 more

Ranked

2^nd among 114 active competitors

Annual Revenue

$100M - $500M as on Dec 31, 2025

Employee Count

833 as on May 31, 2026

Investment & Acquisitions

scPharmaceuticals & 2 more

Similar Companies

Rhythm Pharmaceuticals & 142 more

Exit Details

Public

View MannKind Corp's full profile

MannKind Corp is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Mannkind Corporation CIN: 13-3607736 , United States, Active	Feb 13, 1991	-	349 (As on Dec 31, 2021)	-
Mannkind Corp CIN: 899460 , United States, Active		$100M - $500M (As on Dec 31, 2025)	-	-

MannKind Corp got listed on Jul 28, 2004.

Click here to take a look at MannKind Corp's IPO in detail

MannKind Corp has raised a total funding of $50M over 8 rounds. Its first funding round was on Jan 2004. MannKind Corp has 3 institutional investors.

Here is the list of recent funding rounds of MannKind Corp:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Mar 01, 2021	9348280	Post IPO	3683482	8981427	5116366	6029867
Mar 12, 2018	1276884	Post IPO	5992087	3855570	2178188	2939898
Jul 01, 2013	3159002	Venture Debt	2876489	1040809	5089373	Deerfield

Access funding benchmarks and valuations. Sign up today!

View details of MannKind Corp's funding rounds and investors

MannKind Corp's employee count trend

MannKind Corp has 833 employees as of May 26. Here is MannKind Corp's employee count trend over the years:

Uncover MannKind Corp's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of MannKind Corp include Rhythm Pharmaceuticals, Corcept and 89bio. Here is the list of Top 10 competitors of MannKind Corp, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Rhythm Pharmaceuticals 2010, Boston (United States), Public	Developer of peptide therapeutics for the treatment of rare genetic deficiencies	$84M	Pfizer Venture Investments, Third Rock Ventures ... & 8 others	70/100
2nd	MannKind Corp 1991, Los Angeles (United States), Public	Developer of small-molecule drugs	$50M	Colt Ventures, Deerfield & 1 others	70/100
3rd	Corcept 1998, Menlo Park (United States), Public	Developer of cortisol modulators for the treatment of various diseases	-	Cornerstone Capital, Longitude Capital & 7 others	68/100
4th	89bio 2018, San Francisco (United States), Acquired	Developer of therapies for treating nonalcoholic steatohepatitis and other liver and metabolic disorders	$60M	Longitude Capital, Orbimed & 3 others	64/100
5th	Impel NeuroPharma 2008, Seattle (United States), Public	Developer of an intranasal drug delivery technology for CNS diseases	$120M	VenBio, Vivo Capital & 7 others	63/100
6th	Sernova 1998, London (Canada), Public	Regenerative medicine to deliver proteins and hormones for disease treatment	-	Evotec, National Research Council Canada & 1 others	61/100
7th	Beyond Air 2011, Garden City (United States), Public	Developer of therapeutics for multiple diseases	-	Collage Venture Partners, Cystic Fibrosis Foundation ... Read more	61/100
8th	Genfit 1999, Loos (France), Public	Therapeutics for cardiometabolic and neurodegenerative diseases.	-	Eiffel Investment Group, Ridgeback Capital Management ... & 2 others	59/100
9th	NeOnc Technologies 2008, Los Angeles (United States), Public	Developer of drug delivery methods for pharma-based therapeutics	$18.7M	NIH, S3 Capital	58/100
10th	Alexza 2000, Mountain View (United States), Public	Developer of products for the treatment of acute and intermittent conditions	$97M	Versant Ventures, Delphi Ventures & 16 others	56/100

Get insights and benchmarks for competitors of 2M+ companies! Sign up today!

Looking for more details on MannKind Corp's competitors? Click here to see the top ones

MannKind Corp has acquired 3 companies including scPharmaceuticals, V-Go and Qrumpharma. MannKind Corp has not made any investments as of now.

Here is the list of its acquisitions:

Date of Investment/Acquisition	Type	Company Name	Founded Year	Location
Aug 25, 2025	Acquisition	scPharmaceuticals	2013	Lexington (United States)
May 17, 2022	Acquisition	V-Go	2007	Denmark
Dec 07, 2020	Acquisition	Qrumpharma	2014	Doylestown (United States)